Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients

All NewsFebruary 10, 2026

Phio Pharmaceuticals shares rise after Phase 1b data shows strong safety and tumor clearance for its PH-762 skin cancer drug, with FDA talks planned in 2026.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent